Crossbow Therapeutics, Inc. — Form D
Crossbow Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-04-12. The offering totals $80.0M, of which $37.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-04-12
- Form: D
- Accession: 0001972912-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $80.0M
- Amount sold: $37.6M
- Remaining: $42.4M
- Investors: 15
- Date of first sale: 2023-03-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-478551
Issuer
- Name: Crossbow Therapeutics, Inc.
- CIK: 0001972912
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 1030 Massachusetts Ave, Suite 210, Cambridge, MA, 02138
- Phone: 860-501-1600
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Geraldine Paulus | Executive Officer | Cambridge, MA |
| Alexandra Cantley | Director | Newton, MA |
| Alexander Nolte | Executive Officer | Cambridge, MA |
| Dmitri Wiederschain | Executive Officer | Cambridge, MA |
| Sakae Asanuma | Director | Cambridge, MA |
| Charles Baum | Director | South San Francisco, CA |
| Briggs Morrison | Director | Cambridge, MA |
| Briggs Morrison | Executive Officer | Cambridge, MA |
| Briggs Morrison | Promoter | Cambridge, MA |
| Irena Melnikova | Director | Cambridge, MA |
| Alon Lazarus | Director | Cambridge, MA |
| Todd Foley | Director | South San Francisco, CA |
Other filings by this issuer (1)
More